Advances of acute kidney injury biomarkers in critically ill patients

Abstract:

Acute kidney injury（AKI） is a common disease in intensive care units（ICU），with high mortality. At present，the latest AKI guidelines for clinical practice issued by the Kidney Disease：Improving Global Outcomes（KDIGO） are still taking serum creatinine and urine output as the diagnostic criteria of AKI，having certain limitations to early detect AKI. In recent years，some AKI biomarkers have been verified in the clinical practice，such as neutrophil gelatinase-associated lipid carrier protein，interlukin-18，kidney injury molecule-1，L-type fatty acid binding protein，insulin-like growth factor binding protein-7 and tissue inhibitory metalloproteinases-2，MicroRNA（miRNA），etc. However，these biomarkers are not widely used in ICU because AKI patients in intensive care unit（ICU） have more complicated pathogenesis and pathophysiological changes. This article reviewed the progress in new biomarkers of AKI in critically ill patients in ICU.